Pictet Asset Management
CHRS icon

Pictet Asset Management’s Coherus Oncology CHRS Stock Holding History

Pictet Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,481,848
Closed -$8.26M – 1978
2023
Q4 		$8.26M Buy
2,481,848
+602,392
+32% +$1.61M 0.01% 680
2023
Q3 		$7.03M Buy
+1,879,456
New +$8.68M 0.01% 697

Other funds holding CHRS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Pictet Asset Management's CHRS Position: Q1 2024 in Review

Pictet Asset Management sold out of Coherus Oncology (CHRS) in Q1 2024, closing a stake of 2,481,848 shares — an estimated $8.26M sold.

Pictet Asset Management first reported a position in CHRS in Q3 2023 and held it in 2 quarters. The position peaked at $8.26M in Q4 2023. 137 funds tracked by Wall St. Rank hold CHRS as of Q1 2024.

  • Pictet Asset Management reported no remaining Coherus Oncology position as of Q1 2024 after selling out during the quarter.
  • Pictet Asset Management sold 2,481,848 Coherus Oncology shares in Q1 2024, an estimated $8.26M.
  • Pictet Asset Management first reported a position in Coherus Oncology in Q3 2023 and held it in 2 quarters.
  • Pictet Asset Management's Coherus Oncology position peaked at $8.26M in Q4 2023.
  • 137 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2024.

Based on Pictet Asset Management's 13F filing for Q1 2024, filed 14 May 2024.